for their PD symptoms.
please let us know the form and dose you’re taking and effect you’re noticing.
Thank you.
for their PD symptoms.
please let us know the form and dose you’re taking and effect you’re noticing.
Thank you.
pdkid Farooqji Remcor
from my book....
Iboga, a plant extract from the West African plant Tabernanthe iboga, is traditionally used in spiritual and healing ceremonies.
The main alkaloid compound, ibogaine, has attracted interest in recent years as a potential treatment for various health problems, including addictions and neurodegenerative disorders such as Parkinson's disease.
Potential benefits of iboga for Parkinson's disease
Neuroprotective properties
Ibogaine and related alkaloids have shown neuroprotective properties in preclinical studies. These compounds can reduce neuronal damage and increase the survival rate of neurons, which is particularly important in neurodegenerative diseases such as Parkinson's. By reducing cell stress and inflammation, ibogaine could theoretically help to slow down the progression of the disease.
Promoting the growth of nerve cells
Some studies suggest that ibogaine may stimulate the production of brain-derived neurotrophic factor (BDNF), a protein that promotes the growth and differentiation of new neurons. This could be particularly beneficial for Parkinson's patients, as the loss of dopamine-producing neurons is a central feature of the diseas
Modulation of the dopamine system
Parkinson's disease is characterised by a lack of dopamine in the brain. Ibogaine has been shown to act on the dopaminergic system, possibly modulating dopamine release. This effect could theoretically help to alleviate the symptoms of Parkinson's, although more research is needed to fully understand and confirm these effects.
Research and clinical studies
Research into ibogaine and its use in Parkinson's disease is still in its early stages. Studies and clinical experience to date have focussed mainly on the treatment of addictive disorders. However, there are a growing number of preclinical studies investigating the potential of ibogaine for the treatment of neurodegenerative diseases.
To summarise, iboga and ibogaine have promising potential for the treatment of Parkinson's disease, particularly due to their neuroprotective properties and their ability to promote the growth of nerve cells. Nevertheless, the considerable risks and side effects, especially cardiovascular and neuropsychiatric effects, should not be underestimated. Further research is needed to use these substances safely and effectively in Parkinson's patients.
Intake: From 18 January 2023, I took a microdose of iboga (a root bark with a 5% content) every day for about seven weeks. I took 0.6 grams every morning.
As of 25.3.2023: So far in the first week I have noticed the following changes: less appetite, increased awareness of my surroundings, and feeling a little woozy at times. After a week, my body seems to have got used to taking it and I no longer felt dizzy. So far, however, there has been no change in my Parkinson's symptoms.
Nevertheless, I feel a little more relaxed.
I stopped taking iboga in mid-March 2023 and will start taking it again in January/February 2024 (when I'm always in Thailand).
Status 30.5.2024: I took Iboga again for about 6 weeks in January/February 2024 in Thailand (same dosage). Apparently my body got used to the dosage. I hardly had any side effects like last year.
I will be taking iboga again in Thailand in January/February 2025.
In conversation with Tobias Erny, an expert in the field, I learnt that he is preparing a phase 2 study on the use of Iboga for Parkinson's disease.
The idea behind it is that Iboga promotes the growth of new dopamine neurons in the brain by increasing the nerve growth factor GDNF.
Here is a presentation by Tobias Erny at the University of Zurich:
Frontiers in Psychedelic Science (HS22) – Tobias Erny: Microdosing of Iboga and Ibogaine - UZH (switch.ch) – English